For the second quarter of 2009, total revenues were $1.13 billion, compared to $1.17 billion in the second quarter of 2008.

For the first six months ended June 30, 2009, total revenues were $2.14 billion, compared to $2.25 billion in the same period of 2008. Net earnings net earnings attributable to the company were $220.8 million, or $0.72 per diluted share, compared to $251.1 million, or $0.82 per diluted share, in the same period of 2008.

David Pyott, Allergan's chairman and CEO, said: "Our balanced portfolio of products, the contribution from recently launched products, disciplined execution of our operating plans and management's attention to cost have all contributed to strong financial performance in the second quarter."

A service of YellowBrix, Inc.